{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Complete Response - Score 1"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Very Good Response - Score 2"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Minor Response - Score 3"},{"measurements":[{"groupId":"OG000","value":"11"}],"title":"Stable Disease - Score 4"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Progressive Disease - Score 5"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Unable to Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"title":"Hepatocellular Carcinoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Complete Response - Score 1"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Very Good Response - Score 2"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Minor Response - Score 3"},{"measurements":[{"groupId":"OG000","value":"7"}],"title":"Stable Disease - Score 4"},{"measurements":[{"groupId":"OG000","value":"19"}],"title":"Progressive Disease - Score 5"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Unable to Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Triple Negative Breast Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Complete Response - Score 1"},{"measurements":[{"groupId":"OG000","value":"17"}],"title":"Very Good Response - Score 2"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Minor Response - Score 3"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Stable Disease - Score 4"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"Progressive Disease - Score 5"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Unable to Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"title":"Immune Checkpoint-naïve Melanoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Complete Response - Score 1"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Very Good Response - Score 2"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Minor Response - Score 3"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Stable Disease - Score 4"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Progressive Disease - Score 5"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Unable to Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Primary Refractory Melanoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Complete Response - Score 1"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Very Good Response - Score 2"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Minor Response - Score 3"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Stable Disease - Score 4"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"Progressive Disease - Score 5"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Unable to Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Relapsed Melanoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Complete Response - Score 1"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Very Good Response - Score 2"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Minor Response - Score 3"},{"measurements":[{"groupId":"OG000","value":"15"}],"title":"Stable Disease - Score 4"},{"measurements":[{"groupId":"OG000","value":"24"}],"title":"Progressive Disease - Score 5"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Unable to Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"NSCLC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Complete Response - Score 1"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Very Good Response - Score 2"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Minor Response - Score 3"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"Stable Disease - Score 4"},{"measurements":[{"groupId":"OG000","value":"13"}],"title":"Progressive Disease - Score 5"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Unable to Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"Renal Cell Carcinoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Complete Response - Score 1"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Very Good Response - Score 2"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Minor Response - Score 3"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Stable Disease - Score 4"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"Progressive Disease - Score 5"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Unable to Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Squamous Cell Carcinoma of the Head and Neck"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Complete Response - Score 1"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Very Good Response - Score 2"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Minor Response - Score 3"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"Stable Disease - Score 4"},{"measurements":[{"groupId":"OG000","value":"11"}],"title":"Progressive Disease - Score 5"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Unable to Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Transitional Cell Carcinoma of the GU Tract"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Complete Response - Score 1"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Very Good Response - Score 2"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Minor Response - Score 3"},{"measurements":[{"groupId":"OG000","value":"11"}],"title":"Stable Disease - Score 4"},{"measurements":[{"groupId":"OG000","value":"16"}],"title":"Progressive Disease - Score 5"},{"measurements":[{"groupId":"OG000","value":"7"}],"title":"Unable to Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"Ovarian Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Complete Response - Score 1"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Very Good Response - Score 2"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Minor Response - Score 3"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Stable Disease - Score 4"},{"measurements":[{"groupId":"OG000","value":"11"}],"title":"Progressive Disease - Score 5"},{"measurements":[{"groupId":"OG000","value":"9"}],"title":"Unable to Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"title":"Gastric Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Complete Response - Score 1"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Very Good Response - Score 2"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Minor Response - Score 3"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Stable Disease - Score 4"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Progressive Disease - Score 5"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Unable to Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"MSI high Colorectal Cancer"}],"denoms":[{"counts":[{"groupId":"OG000","value":"382"}],"units":"Participants"}],"description":"Ordinal categorical response score, determined by radiographic disease assessments per irRECIST v1.1. The 5-category ordinal response endpoint is determined at a given timepoint by classifying response into one of the following groups: 1 = Complete response per irRECIST v1.1 2 = Very good response, defined as \\> 60% tumor reduction 3 = Minor response, defined as \\> 30% to ≤ 60% tumor reduction 4 = Stable disease per irRECIST v1.1 5 = Progressive disease per irRECIST v1.1","groups":[{"description":"Epacadostat 100 mg tablet orally BID starting on Cycle 1 Day 1 in combination with pembrolizumab 200 mg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.","id":"OG000","title":"Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Efficacy Evaluable Population included all participants enrolled in the study who received at least 1 dose of study drug (epacadostat or pembrolizumab). Number analyzed indicated participants analyzed in the respective tumor type.","reportingStatus":"POSTED","timeFrame":"Up to 54 months","title":"Phase 2: Ordinal Categorical Response Score","type":"SECONDARY","unitOfMeasure":"Participants"}